Skip to content

Insider · CIK 0001979324

Yekaterina Chudnovsky

directorowner

Files at ELTX (Elicio Therapeutics, Inc.), IMMX (Immix Biopharma, Inc.). First filing -, latest -.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Aug 31, 2026ELTX
Elicio Therapeutics, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+21,750$0.00$021,75040 d ago
Jun 20, 2025IMMX
Immix Biopharma, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+33,000$0.00$033,000Jun 23, 2025
Jun 3, 2025ELTX
Elicio Therapeutics, Inc.
AGrant or award
Warrant (right to buy)derivativeindirect: Held by GKCC, LLC
+103,225$0.00$0103,225Jun 4, 2025
May 19, 2025ELTX
Elicio Therapeutics, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+7,900$0.00$07,900May 20, 2025
Mar 5, 2025ELTX
Elicio Therapeutics, Inc.
CConversion
Common Stockindirect: Held by GKCC, LLC
+3,500,573$5.81$20M5,416,212Mar 7, 2025
Mar 5, 2025ELTX
Elicio Therapeutics, Inc.
CConversion
Convertible Note (convertible into Common Stock)derivativeindirect: Held by GKCC, LLC
-3,442,341$5.81$20M0Mar 7, 2025
Nov 21, 2024ELTX
Elicio Therapeutics, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+4,100$0.00$04,100Nov 25, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Yekaterina Chudnovsky: insider trades and track record | InsiderTell